Interferon-α Treatment in Systemic Mastocytosis

Author(s): Ole Weis Bjerrum.

Journal Name: Current Drug Targets

Volume 12 , Issue 3 , 2011

Become EABM
Become Reviewer


Patients with systemic mastocytosis are rare, constitute a heterogenous clinical entity and some may not require treatment until long after diagnosis. However, most patients who present with disabling symptoms, organ involvement and fulfill B or C findings as outlined in the 2008 WHO classification need treatment. This review on interferon treatment in systemic mastocytosis documents an effect of this biological agent in some patients with mastocytosis. However, the place of interferon-α, as mono- or combination therapy, in the treatment algorithm may only be definitely established in multicenter studies, which are based on the principles of controlled clinical trials.

Keywords: Mast cells, mastocytosis, interferon, classification, treatment, review

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [433 - 436]
Pages: 4
DOI: 10.2174/138945011794815293
Price: $58

Article Metrics

PDF: 15